Radiopharm Theranostics Begins Enrollment for Third Cohort in Phase 1 Trial of 177Lu-RAD204
Radiopharm Theranostics has opened enrollment for the third cohort of its Phase 1 dose-escalation trial of 177Lu-RAD204, after the Data Safety Monitoring Committee cleared escalation to a 90 mCi dose. Early results from the first two cohorts show tumour uptake and a favourable safety profile.
Endometrial Cancer | 15/11/2025 | By Dineshwori
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer
The US FDA has cleared the OncoMate MSI Dx Analysis System as a companion diagnostic to guide pembrolizumab-based combination therapy in advanced endometrial cancer. The PCR-based assay determines microsatellite instability (MSI) status in tumour tissue, with support from Merck, developer of pembrolizumab and lenvatinib.
Endometrial Cancer | 15/11/2025 | By Dineshwori | 185
GSK Enters Oncology in India with Launch of Jemperli and Zejula for Gynaecological Cancers
GSK has launched its much-awaited advanced therapies Jemperli (dostarlimab) and Zejula (niraparib) in India, reinforcing its commitment to addressing the unmet need for gynaecological cancers in the country.
Endometrial Cancer | 25/08/2025 | By Dineshwori | 230
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy